The usefulness of the Lukes-Collins classification in identifying subsets of diffuse histiocytic lymphoma responsive to chemotherapy. 1982

L N Newcomer, and M I Nerenberg, and E C Cadman, and J A Waldron, and L R Farber, and J R Bertino

Twenty-nine patients with Stage III and IV diffuse histiocytic lymphoma (DHL) were treated prospectively with cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone and bleomycin (CHOP-B) or hydroxydaunorubicin, cyclophosphamide, vincristine, methotrexate with leucovorine rescue and cytosine arabinoside (ACOMLA). Twenty-six evaluable patients were reclassified blindly by the Lukes-Collins classification with five large noncleaved follicular center cell (FCC), six large cleaved FCC, three large cell unclassified, seven B-immunoblastic sarcoma and five T-immunoblastic sarcoma patients identified. There was no significant survival advantage between the two combination chemotherapy programs. Survival of the immunoblastic sarcoma patients was inferior to that of the FCC lymphoma patients (P = 0.02). There were no significant survival differences between the large cleaved FCC and noncleaved FCC subtypes. Immunoblastic sarcomas, B- and T-cell types, appear to be more resistant to standard combination chemotherapy programs and new approaches may warrant more aggressive therapy in future protocols. The large cell FCC lymphomas have an excellent prognosis.

UI MeSH Term Description Entries
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016403 Lymphoma, Large B-Cell, Diffuse Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation. Diffuse Large B-Cell Lymphoma,Diffuse, Large B-Cell, Lymphoma,Histiocytic Lymphoma, Diffuse,Lymphoma, Histiocytic, Diffuse,Diffuse Large-Cell Lymphoma,Histiocytic Lymphoma,Large Lymphoid Lymphoma, Diffuse,Large-Cell Lymphoma, Diffuse,Lymphoma, Diffuse Large-Cell,Lymphoma, Histiocytic,Lymphoma, Large Cell, Diffuse,Lymphoma, Large Lymphoid, Diffuse,Lymphoma, Large-Cell, Diffuse,Diffuse Histiocytic Lymphoma,Diffuse Histiocytic Lymphomas,Diffuse Large B Cell Lymphoma,Diffuse Large Cell Lymphoma,Diffuse Large-Cell Lymphomas,Histiocytic Lymphomas,Large Cell Lymphoma, Diffuse,Lymphoma, Diffuse Histiocytic,Lymphoma, Diffuse Large Cell

Related Publications

L N Newcomer, and M I Nerenberg, and E C Cadman, and J A Waldron, and L R Farber, and J R Bertino
January 1978, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
L N Newcomer, and M I Nerenberg, and E C Cadman, and J A Waldron, and L R Farber, and J R Bertino
March 1982, Cancer,
L N Newcomer, and M I Nerenberg, and E C Cadman, and J A Waldron, and L R Farber, and J R Bertino
September 1977, Cancer treatment reports,
L N Newcomer, and M I Nerenberg, and E C Cadman, and J A Waldron, and L R Farber, and J R Bertino
August 1979, The New England journal of medicine,
L N Newcomer, and M I Nerenberg, and E C Cadman, and J A Waldron, and L R Farber, and J R Bertino
January 1987, Voprosy onkologii,
L N Newcomer, and M I Nerenberg, and E C Cadman, and J A Waldron, and L R Farber, and J R Bertino
December 1979, Blood,
L N Newcomer, and M I Nerenberg, and E C Cadman, and J A Waldron, and L R Farber, and J R Bertino
September 1979, The New England journal of medicine,
L N Newcomer, and M I Nerenberg, and E C Cadman, and J A Waldron, and L R Farber, and J R Bertino
January 1979, Acta radiologica: oncology, radiation, physics, biology,
L N Newcomer, and M I Nerenberg, and E C Cadman, and J A Waldron, and L R Farber, and J R Bertino
April 1996, Cutis,
L N Newcomer, and M I Nerenberg, and E C Cadman, and J A Waldron, and L R Farber, and J R Bertino
November 1987, Oral surgery, oral medicine, and oral pathology,
Copied contents to your clipboard!